Patents by Inventor Ryan Michael Fox
Ryan Michael Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230192676Abstract: Disclosed are compounds having the formula (I) wherein R1, R2, and R3 are as defined herein, and methods of making and using the same.Type: ApplicationFiled: December 27, 2018Publication date: June 22, 2023Inventors: Ryan Michael Fox, Philip Anthony Harris, Joerg Holenz, Mark Andrew Seefeld, Ding Zhou
-
Publication number: 20200095217Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: ApplicationFiled: October 17, 2019Publication date: March 26, 2020Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
-
Patent number: 10590135Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: November 19, 2015Date of Patent: March 17, 2020Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
-
Patent number: 10450288Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: GrantFiled: January 9, 2015Date of Patent: October 22, 2019Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
-
Publication number: 20190048016Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: February 14, 2019Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Patent number: 10072011Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: GrantFiled: November 19, 2015Date of Patent: September 11, 2018Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: James Lamond Ellis, Karen Anderson Evans, Ryan Michael Fox, William Henry Miller, Mark Andrew Seefeld
-
Publication number: 20180044338Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: August 4, 2017Publication date: February 15, 2018Inventors: Charles A. BLUM, Richard Dana CALDWELL, Rebecca CASAUBON, Jeremy S. DISCH, Ryan Michael FOX, Karsten KOPPETSCH, Pui Yee NG, Christopher OALMANN, Robert B. PERNI, Bruce G. SZCZEPANKIEWICZ, Brian H. WHITE
-
Publication number: 20170362234Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: December 21, 2017Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Publication number: 20170355705Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.Type: ApplicationFiled: November 19, 2015Publication date: December 14, 2017Inventors: James Lamond ELLIS, Karen Anderson EVANS, Ryan Michael FOX, William Henry MILLER, Mark Andrew SEEFELD
-
Publication number: 20170355697Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: November 19, 2015Publication date: December 14, 2017Inventors: Charles A. BLUM, Richard Dana CALDWELL, Rebecca CASAUBON, Jeremy S. DISCH, Ryan Michael FOX, Karsten KOPPETSCH, William Henry MILLER, Pui Yee NG, Christopher OALMANN, Robert B. PERNI, Bruce G. SZCZEPANKIEWICZ, Brian H. WHITE
-
Patent number: 9834558Abstract: The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: November 19, 2014Date of Patent: December 5, 2017Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian White
-
Patent number: 9765075Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: May 13, 2014Date of Patent: September 19, 2017Assignee: GLAXOSMITHKLINE LLCInventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
-
Publication number: 20160340328Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.Type: ApplicationFiled: January 9, 2015Publication date: November 24, 2016Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
-
Publication number: 20160083386Abstract: Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: May 13, 2014Publication date: March 24, 2016Inventors: Charles A. BLUM, Richard Dana CALDWELL, Rebecca CASAUBON, Jeremy S. DISCH, Ryan Michael FOX, Karsten KOPPETSCH, Pui Yee NG, Christopher OALMANN, Robet B. PERNI, Bruce G. SZCZEPANKIEWICZ, Brian H. WHITE
-
Publication number: 20150152108Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: November 19, 2014Publication date: June 4, 2015Inventors: Charles A. BLUM, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee NG, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian White
-
Patent number: 8450484Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: GrantFiled: July 24, 2009Date of Patent: May 28, 2013Assignee: GlaxoSmithKline, LLCInventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
-
Patent number: 8431590Abstract: The present invention relates to a compound of the following formula: where R1-R6, R10, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.Type: GrantFiled: June 20, 2008Date of Patent: April 30, 2013Assignee: Glaxo Group LimitedInventors: Brian W. Budzik, Hilary Schenck Eidam, Ryan Michael Fox, Krista B. Goodman, Dimitar B. Gotchev, Pamela A. Haile, Terry Vincent Hughes, Ronggang Liu, Nathan A. Miller, Tamara Ann Miskowski, Clark A. Sehon, Andrew Q. Viet, Gren Z. Wang, Jing Zhang
-
Publication number: 20110130400Abstract: The present invention relates to diazabicyclo[2.2.1]hept-2-yl analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.Type: ApplicationFiled: July 24, 2009Publication date: June 2, 2011Inventors: Michael Jonathan Bury, Mui Cheung, Hilary Schenck Eidam, Ryan Michael Fox, Krista Goodman, Eric Steven Manas
-
Publication number: 20110034499Abstract: The present invention relates to a compound of the following formula: where R1-R6, R10, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.Type: ApplicationFiled: June 20, 2008Publication date: February 10, 2011Inventors: Brian W. Budzik, Hilary Schenck Eidam, Ryan Michael Fox, Krista B. Goodman, Dimitar B. Gotchev, Pamela A. Haile, Terry Vincent Hughes, Ronggang Liu, Nathan A. Miller, Tamara Ann Miskowski, Clark A. Sehon, Andrew Q. Viet, Gren Z. Wang, Jing Zhang